Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
EOLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.67 - $17.82
Previous CloseN/A
Volume344.54K
Average Volume (3M)899.94K
Market Cap
$606.62M
Enterprise Value$1.07B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 13, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding63,586,754
10 Day Avg. Volume1,203,294
30 Day Avg. Volume899,940
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.11
Price to Cash Flow (P/CF)43.10
P/FCF Ratio60.10
Enterprise Value/Market Cap1.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.92
Enterprise Value/Ebitda-23.78
Forecast
1Y Price Target
$24.83Price Target Upside160.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Evolus News
---
Bulls Say, Bears Say
Bulls Say
ProfitabilityEOLS is on track for profitability in 2025, with a reiterated goal of achieving $700 million in revenues by 2028.
Regulatory ApprovalThe FDA approved Evolysse for facial lines and folds, making it the first HA filler to include wrinkles from weight loss in the label.
Revenue GrowthThe strong sales performance in 4Q enabled the company to achieve full-year profitability with a positive non-GAAP operating income of $0.3M for 2024, one year ahead of expectations.
Bears Say
Earnings ImpactThe 4Q24 earnings update was mostly a non-event, given the company's prior disclosures and thus is unlikely to drive major EOLS share movements.
Economic EnvironmentThe current economic environment has brought significant uncertainty and dynamics that management could not have anticipated.
Economic SensitivityThe dermal filler market is more economically sensitive given the higher price point.
---
Ownership Overview
3.57% Insiders
10.14% Mutual Funds
46.69% Other Institutional Investors
28.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $8.67 and its highest was $17.82 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $606.62M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is May 13, 2025 which is in 29 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Mar 04, 2025. The company reported $0.033 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.025.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -0.12.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 63,586,754 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of $0.033 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went down -1.254%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
---
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.83 (160.27% Upside)
$24.83 (160.27% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 620.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $167.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.4%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.82%
12-Months-Change
Fundamentals
Return on Equity
-913.07%
Trailing 12-Months
Asset Growth
23.05%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
---
EOLS Company Deck
---
EOLS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Evolus demonstrated strong financial performance with significant revenue growth and profitability achieved ahead of schedule, along with successful product approvals and market expansion. However, there are concerns regarding market conditions and managing cash flow in Q1 2025.Read More>---
EOLS Stock 12 Month Forecast
Average Price Target
$24.83
▲(160.27% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Tilray
―
Best Analysts Covering EOLS
1 Year
1 Year Success Rate
15/30 ratings generated profit
1 Year Average Return
+8.30%
reiterated a buy rating last month
Copying Marc Goodman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +8.30% per trade.
---